- Home
- ESEA vs ADCT Comparison
ESEA vs ADCT Comparison
Compare ESEA & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ESEA
- ADCT
- Stock Information
- Founded
- ESEA 2005
- ADCT 2011
- Country
- ESEA Greece
- ADCT Switzerland
- Employees
- ESEA N/A
- ADCT N/A
- Industry
- ESEA Marine Transportation
- ADCT Biotechnology: Pharmaceutical Preparations
- Sector
- ESEA Consumer Discretionary
- ADCT Health Care
- Exchange
- ESEA Nasdaq
- ADCT Nasdaq
- Market Cap
- ESEA 208.2M
- ADCT 241.0M
- IPO Year
- ESEA 2006
- ADCT 2020
- Fundamental
- Price
- ESEA $45.57
- ADCT $2.68
- Analyst Decision
- ESEA Strong Buy
- ADCT Strong Buy
- Analyst Count
- ESEA 1
- ADCT 6
- Target Price
- ESEA $62.00
- ADCT $7.80
- AVG Volume (30 Days)
- ESEA 42.6K
- ADCT 947.2K
- Earning Date
- ESEA 06-18-2025
- ADCT 08-05-2025
- Dividend Yield
- ESEA 5.68%
- ADCT N/A
- EPS Growth
- ESEA 21.86
- ADCT N/A
- EPS
- ESEA 18.62
- ADCT N/A
- Revenue
- ESEA $222,525,034.00
- ADCT $75,817,000.00
- Revenue This Year
- ESEA $5.14
- ADCT $10.65
- Revenue Next Year
- ESEA $3.76
- ADCT $15.05
- P/E Ratio
- ESEA $2.40
- ADCT N/A
- Revenue Growth
- ESEA 14.62
- ADCT 10.49
- 52 Week Low
- ESEA $24.58
- ADCT $1.05
- 52 Week High
- ESEA $50.82
- ADCT $4.13
- Technical
- Relative Strength Index (RSI)
- ESEA 65.27
- ADCT 44.48
- Support Level
- ESEA $43.60
- ADCT $2.59
- Resistance Level
- ESEA $47.88
- ADCT $2.98
- Average True Range (ATR)
- ESEA 2.01
- ADCT 0.29
- MACD
- ESEA -0.20
- ADCT -0.13
- Stochastic Oscillator
- ESEA 44.03
- ADCT 5.63
About ESEA Euroseas Ltd. (Marshall Islands)
Euroseas Ltd is a shipping company. Its fleet consists of containerships that transport container boxes providing scheduled service between ports. Its operations are managed by an affiliated ship management company, which is responsible for the day-to-day commercial and technical management and operations of the vessels. The company employs its vessels on spot and period charters and through pool arrangements.
About ADCT ADC Therapeutics SA
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).